Woodline Partners LP Acquires 41,711 Shares of GH Research PLC (NASDAQ:GHRS)

Woodline Partners LP increased its stake in shares of GH Research PLC (NASDAQ:GHRS - Free Report) by 112.0% during the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 78,949 shares of the company's stock after purchasing an additional 41,711 shares during the period. Woodline Partners LP owned 0.15% of GH Research worth $553,000 as of its most recent SEC filing.

Other institutional investors have also added to or reduced their stakes in the company. BNP Paribas Financial Markets purchased a new stake in GH Research during the 4th quarter worth about $44,000. Two Sigma Investments LP purchased a new stake in GH Research during the 4th quarter worth about $117,000. Millennium Management LLC purchased a new stake in GH Research during the 4th quarter worth about $145,000. AdvisorShares Investments LLC lifted its holdings in GH Research by 15.4% during the 4th quarter. AdvisorShares Investments LLC now owns 36,011 shares of the company's stock worth $252,000 after purchasing an additional 4,806 shares in the last quarter. Finally, Northern Trust Corp lifted its holdings in GH Research by 26.8% during the 4th quarter. Northern Trust Corp now owns 40,834 shares of the company's stock worth $286,000 after purchasing an additional 8,641 shares in the last quarter. Hedge funds and other institutional investors own 56.90% of the company's stock.

Analyst Ratings Changes

Several analysts have weighed in on GHRS shares. HC Wainwright reaffirmed a "buy" rating and issued a $40.00 price target on shares of GH Research in a report on Friday, May 9th. Stifel Nicolaus raised their price target on GH Research from $18.00 to $32.00 and gave the company a "buy" rating in a report on Thursday, February 27th. Cantor Fitzgerald raised GH Research to a "strong-buy" rating in a report on Tuesday, May 13th. Guggenheim lowered their price target on GH Research from $32.00 to $29.00 and set a "buy" rating on the stock in a report on Friday, May 9th. Finally, Royal Bank of Canada started coverage on GH Research in a report on Friday, March 7th. They issued an "outperform" rating and a $31.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a buy rating and one has given a strong buy rating to the company. According to MarketBeat, GH Research presently has a consensus rating of "Moderate Buy" and a consensus price target of $30.43.

GH Research Stock Down 0.8%

Shares of NASDAQ GHRS traded down $0.10 during trading hours on Friday, reaching $11.98. 112,717 shares of the stock traded hands, compared to its average volume of 183,191. The company has a market capitalization of $623.30 million, a P/E ratio of -15.16 and a beta of 0.86. GH Research PLC has a 52-week low of $6.00 and a 52-week high of $20.50. The company's 50-day simple moving average is $10.31 and its two-hundred day simple moving average is $10.16.

GH Research (NASDAQ:GHRS - Get Free Report) last announced its quarterly earnings data on Thursday, May 8th. The company reported ($0.19) earnings per share for the quarter, beating analysts' consensus estimates of ($0.61) by $0.42. As a group, sell-side analysts forecast that GH Research PLC will post -0.8 earnings per share for the current fiscal year.

About GH Research

GH Research PLC, together with its subsidiary GH Research Ireland Limited, engages in developing various therapies to treat psychiatric and neurological disorders. It is involved in the development of 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) therapies for the treatment of patients with treatment-resistant depression (TRD).